LOX-1 in atherosclerotic disease

Tatsuya Sawamura, Ichiro Wakabayashi, Tomonori Okamura

研究成果: Article

27 引用 (Scopus)

抄録

Oxidized low-density lipoprotein (LDL) exhibits various biological activities and accumulates in atheromas. LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates oxidized LDL activity in vascular endothelial cells. Activation of LOX-1 results in oxidized LDL-induced endothelial dysfunction and hyperlipidemia-induced vascular lipid deposition. We hypothesized that LOX-1 is a candidate risk factor beyond LDL cholesterol (LDLC) and developed a novel assay to quantify LOX-1 ligand containing apoB (LAB). In men from the United States, serum LAB showed a significant positive association with carotid intima-media thickness, independent of LDLC. LAB and the LOX index (obtained by multiplying LAB by sLOX-1) were significantly associated with the incidence of coronary artery disease and ischemic stroke after adjusting for confounding factors, including non-HDL cholesterol. sLOX-1 is thought to be a better biomarker for early diagnosis of acute coronary syndrome than traditional biomarkers, including troponin T. LAB was associated with various atherosclerotic risk factors such as smoking, obesity, diabetes, diastolic hypertension, hypertriglyceridemia, and metabolic syndrome. Measurement of the soluble form of LOX-1 (sLOX-1) and LAB seems to be useful for evaluating the state and risk of atherosclerosis and atherosclerosis-related diseases. Further prospective studies using large populations and randomized clinical trials on sLOX-1, LAB, and the LOX index are needed.

元の言語English
ページ(範囲)157-163
ページ数7
ジャーナルClinica Chimica Acta
440
DOI
出版物ステータスPublished - 2015 2 2

Fingerprint

Apolipoproteins B
Ligands
Biomarkers
LDL Cholesterol
Atherosclerosis
Class E Scavenger Receptors
Carotid Intima-Media Thickness
Troponin T
Hypertriglyceridemia
Endothelial cells
Atherosclerotic Plaques
Acute Coronary Syndrome
Medical problems
Bioactivity
Hyperlipidemias
Blood Vessels
Coronary Artery Disease
Early Diagnosis
Assays
Randomized Controlled Trials

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

これを引用

LOX-1 in atherosclerotic disease. / Sawamura, Tatsuya; Wakabayashi, Ichiro; Okamura, Tomonori.

:: Clinica Chimica Acta, 巻 440, 02.02.2015, p. 157-163.

研究成果: Article

Sawamura, Tatsuya ; Wakabayashi, Ichiro ; Okamura, Tomonori. / LOX-1 in atherosclerotic disease. :: Clinica Chimica Acta. 2015 ; 巻 440. pp. 157-163.
@article{2a3cc85903164b0d930cc2cccb062274,
title = "LOX-1 in atherosclerotic disease",
abstract = "Oxidized low-density lipoprotein (LDL) exhibits various biological activities and accumulates in atheromas. LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates oxidized LDL activity in vascular endothelial cells. Activation of LOX-1 results in oxidized LDL-induced endothelial dysfunction and hyperlipidemia-induced vascular lipid deposition. We hypothesized that LOX-1 is a candidate risk factor beyond LDL cholesterol (LDLC) and developed a novel assay to quantify LOX-1 ligand containing apoB (LAB). In men from the United States, serum LAB showed a significant positive association with carotid intima-media thickness, independent of LDLC. LAB and the LOX index (obtained by multiplying LAB by sLOX-1) were significantly associated with the incidence of coronary artery disease and ischemic stroke after adjusting for confounding factors, including non-HDL cholesterol. sLOX-1 is thought to be a better biomarker for early diagnosis of acute coronary syndrome than traditional biomarkers, including troponin T. LAB was associated with various atherosclerotic risk factors such as smoking, obesity, diabetes, diastolic hypertension, hypertriglyceridemia, and metabolic syndrome. Measurement of the soluble form of LOX-1 (sLOX-1) and LAB seems to be useful for evaluating the state and risk of atherosclerosis and atherosclerosis-related diseases. Further prospective studies using large populations and randomized clinical trials on sLOX-1, LAB, and the LOX index are needed.",
keywords = "Apolipoprotein B, Atherogenesis, Cardiovascular disease, Endothelial cell, Oxidized low-density lipoprotein, Scavenger receptor",
author = "Tatsuya Sawamura and Ichiro Wakabayashi and Tomonori Okamura",
year = "2015",
month = "2",
day = "2",
doi = "10.1016/j.cca.2014.11.016",
language = "English",
volume = "440",
pages = "157--163",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - LOX-1 in atherosclerotic disease

AU - Sawamura, Tatsuya

AU - Wakabayashi, Ichiro

AU - Okamura, Tomonori

PY - 2015/2/2

Y1 - 2015/2/2

N2 - Oxidized low-density lipoprotein (LDL) exhibits various biological activities and accumulates in atheromas. LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates oxidized LDL activity in vascular endothelial cells. Activation of LOX-1 results in oxidized LDL-induced endothelial dysfunction and hyperlipidemia-induced vascular lipid deposition. We hypothesized that LOX-1 is a candidate risk factor beyond LDL cholesterol (LDLC) and developed a novel assay to quantify LOX-1 ligand containing apoB (LAB). In men from the United States, serum LAB showed a significant positive association with carotid intima-media thickness, independent of LDLC. LAB and the LOX index (obtained by multiplying LAB by sLOX-1) were significantly associated with the incidence of coronary artery disease and ischemic stroke after adjusting for confounding factors, including non-HDL cholesterol. sLOX-1 is thought to be a better biomarker for early diagnosis of acute coronary syndrome than traditional biomarkers, including troponin T. LAB was associated with various atherosclerotic risk factors such as smoking, obesity, diabetes, diastolic hypertension, hypertriglyceridemia, and metabolic syndrome. Measurement of the soluble form of LOX-1 (sLOX-1) and LAB seems to be useful for evaluating the state and risk of atherosclerosis and atherosclerosis-related diseases. Further prospective studies using large populations and randomized clinical trials on sLOX-1, LAB, and the LOX index are needed.

AB - Oxidized low-density lipoprotein (LDL) exhibits various biological activities and accumulates in atheromas. LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates oxidized LDL activity in vascular endothelial cells. Activation of LOX-1 results in oxidized LDL-induced endothelial dysfunction and hyperlipidemia-induced vascular lipid deposition. We hypothesized that LOX-1 is a candidate risk factor beyond LDL cholesterol (LDLC) and developed a novel assay to quantify LOX-1 ligand containing apoB (LAB). In men from the United States, serum LAB showed a significant positive association with carotid intima-media thickness, independent of LDLC. LAB and the LOX index (obtained by multiplying LAB by sLOX-1) were significantly associated with the incidence of coronary artery disease and ischemic stroke after adjusting for confounding factors, including non-HDL cholesterol. sLOX-1 is thought to be a better biomarker for early diagnosis of acute coronary syndrome than traditional biomarkers, including troponin T. LAB was associated with various atherosclerotic risk factors such as smoking, obesity, diabetes, diastolic hypertension, hypertriglyceridemia, and metabolic syndrome. Measurement of the soluble form of LOX-1 (sLOX-1) and LAB seems to be useful for evaluating the state and risk of atherosclerosis and atherosclerosis-related diseases. Further prospective studies using large populations and randomized clinical trials on sLOX-1, LAB, and the LOX index are needed.

KW - Apolipoprotein B

KW - Atherogenesis

KW - Cardiovascular disease

KW - Endothelial cell

KW - Oxidized low-density lipoprotein

KW - Scavenger receptor

UR - http://www.scopus.com/inward/record.url?scp=84913572966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913572966&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.11.016

DO - 10.1016/j.cca.2014.11.016

M3 - Article

C2 - 25463747

AN - SCOPUS:84913572966

VL - 440

SP - 157

EP - 163

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -